Vanadom

Quick links to important sections

Vanadom

Method of action: Skeletal Muscle Relaxant

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vanadom

What is Vanadom?

Property Description
Active ingredient Carisoprodol
Form Oral Tablet
Pharmacological class Centrally acting Skeletal Muscle Relaxant (SMR)
Common use Relieving discomfort from acute muscle spasms
Origin Synthetic compound (Carbamate derivative)

Vanadom: Classification and Core Identity

Vanadom is a medication whose active ingredient is Carisoprodol, classifying it as a centrally acting skeletal muscle relaxant (SMR). This compound is a prescription-only medication approved for use in adults. Carisoprodol is defined by its action within the central nervous system (CNS), where it is known to interfere with communication between nerves in the spinal cord and the brainstem, a mechanism that is clinically recognized for differentiating it from agents that act directly on muscle tissue. The SMR classification is utilized to describe the drug's therapeutic nature in settings where the reduction of excessive muscle spasm activity is required.

Composition, Origin, and Pharmaceutical Form

The preparation containing Carisoprodol is administered via the oral route of administration and is most frequently encountered as a tablet formulation. The active substance itself is a synthetic compound, chemically identified as a carbamate derivative. Carisoprodol is metabolized into Meprobamate, which is recognized for possessing inherent sedative properties. This chemical origin as a synthetic derivative and its final form as a standardized, single-ingredient oral tablet ensures predictable pharmaceutical delivery. A key differentiating feature is this active metabolic conversion, which contributes significantly to the overall central effects.

General Purpose of this Skeletal Muscle Relaxant

The general purpose of a medication containing Carisoprodol is to provide muscle relaxation to relieve discomfort associated with acute, painful musculoskeletal conditions, such as those arising from a common muscle strain or injury. It is intended to function as an adjunct to rest and physical therapy, not as a solitary treatment. This centrally mediated action helps interrupt the cyclical spasms and pain by damping down the underlying nervous system hyperactivity, thereby facilitating the body’s ability to rest and recover. The effect is typically limited to short-term use due to the acute nature of its indication.

Regulatory References

  1. Carisoprodol Metabolism to Meprobamate (NIH/NCBI)

What side effects are possible with Vanadom?

Vanadom: Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Vanadom (Carisoprodol) as outlined in regulatory documents.

Adverse Reaction Scope

The safety profile is characterized by effects categorized across several physiological systems, with a strong focus on the Central Nervous System (CNS) Disorders.

Classification Documented Effects
Common Adverse Reactions Drowsiness, dizziness, and headache are the most frequently reported effects listed in regulatory documents.
System-Organ Classes Effects are noted in the Nervous System (e.g., tremor, paresthesia), Psychiatric (e.g., insomnia, agitation, depression), Gastrointestinal (e.g., nausea, vomiting), and Cardiovascular systems (e.g., tachycardia, postural hypotension).

Serious Safety Considerations

The official labeling highlights specific serious adverse reactions, including the potential for seizures and severe, generalized idiosyncratic reactions such as transient quadriplegia. Additionally, the risk of developing drug dependence and subsequent withdrawal syndrome is a documented safety pattern associated with prolonged use.

Population-Specific and Use Restrictions

Safety notes advise caution for use in older adults due to increased susceptibility to CNS effects. Caution is also noted for patients with hepatic impairment or renal impairment as the elimination of the medication may be altered. The medication is contraindicated in patients with a history of acute intermittent porphyria and those with known hypersensitivity to Carisoprodol or its metabolite, Meprobamate. Regulatory documents also include safety warnings regarding the combined use with other CNS depressants, citing the risk of increased sedative effects.

Overdose and Emergency Response

The official regulatory profile for a Vanadom (Carisoprodol) overdose details specific manifestations and mandated emergency actions. Overdosage is often characterized by signs of Central Nervous System (CNS) depression, which may include confusion, muscular incoordination, blurred vision, nystagmus, and rigidity. Paradoxical CNS stimulation has also been documented. Severe overdose can rapidly escalate to life-threatening outcomes such as respiratory depression, seizures, shock, and coma. Serotonin syndrome is also a reported complication in cases of intoxication.

Immediate medical attention is required for any suspected overdose or for the onset of severe signs. Regulatory guidance mandates that basic life support measures be instituted and that a Poison Control Center be contacted for specialized management information. The overdose risk is officially stated to be additive when Vanadom is combined with alcohol or other CNS depressants.

Management of an overdosage is exclusively symptomatic and supportive, as there is no specific antidote. Procedural measures described include the consideration of gastric lavage soon after ingestion. Induced vomiting (emesis) is not recommended due to the high risk of compromising the airway. In cases of severe CNS depression, actions such as tracheal intubation for airway protection and circulatory support using volume infusion and pressor agents may be necessary. Seizures must be treated with intravenous benzodiazepines.

Therapeutic Uses of Vanadom

What Vanadom Treats: Main Uses and Benefits

This medication is primarily used to provide symptomatic relief from acute, painful muscle spasms associated with short-term musculoskeletal conditions, such as injuries or strains. The medication is used to address a cluster of symptoms associated with acute musculoskeletal conditions, which include involuntary muscle tightness, cramping, associated tenderness, and limitation of motion. The medication may be part of symptomatic management as an adjunct to rest and physical therapy, and is relevant when supportive symptom management is appropriate.


Vanadom is applied in clinical scenarios where symptoms create noticeable interference with daily stability due to heightened discomfort. It is commonly used across conditions characterized by periods of heightened symptoms—like stiffness and pain—that temporarily disrupt normal functioning. By easing the overall symptom load, the medication supports patients during difficult episodes of heightened discomfort.

“Vanadom is commonly used to support patients during episodes of acute muscle pain and stiffness caused by temporary conditions.”

This medication is commonly used to help with the management of muscle spasm, providing support for associated pain, and assisting with easing limited movement. The medication supports patients during symptomatic phases.

Therapeutic Scope: Relief for Acute Muscle Spasms and Pain

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vanadom

Official regulatory information defines the eligible patient population for Vanadom (Carisoprodol) based on absolute contraindications, age restrictions, and specific health conditions.


Eligibility Scope

Category Regulatory Status / Restriction
Populations for whom use is allowed Adults with acute, painful musculoskeletal conditions.
Populations for whom use is contraindicated Patients with a history of acute intermittent porphyria.
Patients with known hypersensitivity to Carisoprodol or its metabolite, Meprobamate.
Age-related eligibility rules Not recommended for patients under 16 years of age; safety and efficacy have not been established.
Older adults (ge 65 years) require caution due to increased risk of CNS effects.
Condition-specific eligibility rules Caution is advised for patients with renal impairment or hepatic impairment due to the drug's metabolism and excretion.
Caution is mandatory for patients with a history of drug abuse or pre-existing CNS depression or seizures.
Pregnancy and lactation eligibility status Pregnancy: Data have not identified an increased risk of birth defects, but use is conditional. Lactation: The drug is excreted into human milk; caution is recommended.
Eligibility-related restrictions Use is limited to a short duration of up to two or three weeks, as effectiveness for more prolonged use is not established.

Resulting Eligibility Structure

Official prescribing information establishes absolute prohibitions for certain metabolic disorders and hypersensitivity, primarily limiting use to adults for short-term treatment periods. Eligibility is conditional upon the patient's underlying health status, requiring caution for those with impaired organ function or heightened risk for dependence or CNS effects.

What should I know about interactions with other medicines?

Vanadom Interactions with other medicines and products

The interaction profile for Vanadom (Carisoprodol) is defined by its effects on the central nervous system (CNS) and its metabolic pathway.


Pharmacodynamic Interactions

Co-administration of Vanadom with other Central Nervous System (CNS) depressants may result in additive sedative effects. Products documented to cause this include opioids, benzodiazepines, and tricyclic antidepressants. The use of alcohol is formally restricted and must be avoided due to the documented increase in CNS depression. Concomitant use with the active metabolite, Meprobamate, is not recommended due to additive pharmacologic effects.


Pharmacokinetic (Metabolic) Interactions

Carisoprodol is primarily metabolized by the CYP2C19 enzyme. Interactions with other medicines modify the plasma concentration of the drug and its metabolite. CYP2C19 inhibitors (such as Omeprazole or Fluvoxamine) are documented to increase the exposure of Carisoprodol. Conversely, CYP2C19 inducers (such as Rifampin or the herbal product St. John's Wort) are documented to decrease Carisoprodol exposure. Individuals who are genetic CYP2C19 poor metabolizers are noted in regulatory information to have significantly higher Carisoprodol exposure. Taking the medication with a high-fat meal has no effect on its pharmacokinetics.

Mechanism of Action

How Vanadom Works

Vanadom functions by selectively inhibiting the activity of osteoclasts, which are the specialized cells responsible for bone resorption. By modulating this activity, it shifts the balance between bone formation and resorption, thereby favoring bone mineral accrual and decreasing the localized proteolytic and acidic dissolution of the bone matrix.

The drug is a pyrophosphate analog that binds directly and irreversibly to the active site of the ATPase proton pump located in the osteoclast's ruffled border. This specific binding event causes an immediate blockade of proton efflux into the resorption lacuna. Since proton efflux is the final step in the acidification process required to dissolve the underlying bone matrix, this cascade modulation leads directly to a reduction in bone demineralization.

The resulting mechanistic effect on the ruffled border inhibits the osteoclast's inherent resorptive capacity. This action limits the release of hydroxyapatite crystals from the bone surface, which leads to an increased relative bone mineral density across the skeletal system.

Dosage and Administration Information

Administration of Vanadom: Official Usage Guidelines

Vanadom, whose active ingredient is Carisoprodol, is intended for use according to strict administration protocols. The medication is an oral tablet and is available in strengths of 250 mg and 350 mg.


Labeled Dosing and Duration

The standard dosage for adults is 250 mg to 350 mg per dose. This dose is taken multiple times per day, specifically three times a day and at bedtime, resulting in a total of four administrations within a 24-hour period. Official labeling restricts the total duration of use to short periods, not exceeding two or three weeks.


Administration Context and Population Limits

  • Intake Context: The tablet may be administered with or without food.
  • Pediatric Use: The medication is not recommended for use in patients under 16 years of age.
  • Missed Dose: If a dose is missed, patients should not take a double dose to compensate, but should instead return to their regular dosing schedule.
  • Discontinuation: If the medication has been taken for a prolonged period (beyond the recommended short duration), cessation may require a gradual reduction in dose.

Resulting Procedural Structure

These official instructions establish the complete procedural structure for using the medicine. The process begins with the oral administration of a 250 mg or 350 mg dose, followed by a mandated four-times-daily frequency throughout the course of treatment. This usage is officially time-limited to a maximum of two to three weeks, which defines the standard, acute-treatment context for the medicine. These limits and conditions define the regulated, high-level use pattern of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vanadom

Research Evidence for Acute Musculoskeletal Spasm

Research exploring the effects of this compound has primarily focused on how study participants with conditions associated with acute or disruptive episodes were observed in the controlled setting, such as painful muscle spasms, often in the lower back. The most definitive evidence comes from short-term, randomized controlled trials (RCTs). These studies involved comparing the medication against an inactive placebo. This design allowed researchers to monitor outcomes related to physical discomfort and to study patterns related to systemic or functional imbalance. Systematic reviews and meta-analyses, which aggregate data from these individual trials, contribute to the broader evidence landscape by summarizing patterns observed in previous trials.

Outcomes Measured in Clinical Trials

Studies monitored patient-reported outcomes describing perceived discomfort as the main axes of evaluation using standardized tools. This included pain intensity scales and the patient's overall impression of change or relief from their starting symptoms. Beyond comfort, research also explored outcomes reflecting daily functioning or activity level. Researchers used validated questionnaires to assess functional measures related to movement and ability. The findings describe patterns observed in the studies related to temporary physiological imbalance and the challenges of daily functioning associated with acute symptoms.

Duration of Studies and Follow-Up Data

The vast majority of controlled efficacy research for Vanadom was studied for short, defined time intervals. Many key studies monitored responses only over a period of seven days, with some follow-up extending up to two or three weeks. These short follow-up durations were limited because the medication is intended for temporary symptom management. Long-term effects are not fully established, and there are no controlled studies designed to evaluate patterns related to chronic or ongoing conditions. The evidence highlights what is known for temporary use. Data exploring patterns outside of this acute setting are still emerging.

Evidence in Specific Patient Populations

The primary study populations for Vanadom were composed of general adults (aged 18 to 70). However, data for certain groups remain insufficient. For instance, the research has not established adequate evidence for the use of the drug in pediatric patients (under 16). Similarly, evidence regarding the drug was not a focus of the primary efficacy trials for older adults (typically 65 and over). Research describes how drug exposure may vary between individuals based on specific metabolic differences (like CYP2C19 metabolizer status).

Key Limitations and Research Uncertainty

The research landscape includes several important limitations. Follow-up durations were limited, meaning any findings describe group patterns related only to short-term episodes. Comparative evidence is lacking, as studies exploring the drug's relative performance against many other commonly used treatments are few. Evidence quality varies across studies, with some trials showing patterns related to heterogeneity or limitations. Therefore, while Vanadom was studied for acute symptom relief, certainty remains low regarding the long-term patterns observed in patients, and subgroup findings are uncertain for vulnerable populations.

Key Studies & References

  1. CARISOPRODOL - Highlights of Prescribing Information (FDA/DailyMed)
  2. Carisoprodol Therapy and CYP2C19 Genotype - Medical Genetics Summaries (NCBI - NIH)

Frequently Asked Questions (FAQ)

Common questions about Vanadom (FAQ)

Q: How quickly can a person expect to see any changes after starting Vanadom?

According to the official prescribing information, the effects of Vanadom generally begin within approximately half an hour after taking a single dose. This early onset of action is consistent with its intended use for short-term relief of acute conditions.

Q: Is it true that Vanadom might cause changes in body weight?

Official regulatory documents list all known common and serious adverse reactions for Vanadom. However, changes in body weight, such as weight gain or weight loss, are not listed among the documented adverse reactions in these official records.

Q: Are there any restrictions on receiving vaccinations while taking Vanadom?

Regulatory labeling for the active ingredient in Vanadom, Carisoprodol, contains extensive information on drug interactions and use restrictions. The labeling does not explicitly list restrictions or interactions regarding receiving vaccinations while the medication is being used.

Q: Does Vanadom change the effectiveness of hormonal birth control methods?

The official prescribing information provides detailed sections on known drug interactions. These sections do not explicitly state an interaction between the active ingredient in Vanadom and hormonal birth control methods.

Q: What kind of regular monitoring, like blood tests, is sometimes recommended with Vanadom?

Official regulatory information advises caution when Vanadom is used in patients with known renal (kidney) or hepatic (liver) impairment. Caution in these conditions suggests that clinical monitoring is often undertaken by healthcare providers.

Q: Is there a generic alternative to the Vanadom brand name available?

Yes, the active ingredient in Vanadom, which is Carisoprodol, is an approved substance. This means the medication is available under its chemical name as a generic formulation.

Q: How long does the primary effect of a single Vanadom dose usually last?

Studies and official information indicate that the primary effects of a single dose of Vanadom typically last for a duration of approximately four to six hours. This timeframe is consistent with its intended short-term usage pattern.

Q: Does taking Vanadom make a person more sensitive to sun exposure?

Official regulatory documents list all known and common side effects of the medication. Increased sun sensitivity or photosensitivity is not listed among the documented adverse reactions in these official records.

Q: What is the shelf life or typical expiration date of Vanadom when stored properly?

The drug label specifies controlled room temperature and protection from moisture and freezing to ensure the stability of the product. The specific shelf life and expiration date are determined by the manufacturer per lot and are always printed directly on the packaging.

Q: What does it mean if a regulatory source lists Vanadom as a high-alert medication?

The regulatory document highlights the potential for serious side effects, including sedation, Central Nervous System (CNS) depression, and seizures. Official warnings describe the risk of impaired judgment during activities like driving or operating heavy machinery.

Q: Are there any specific foods, drinks, or dietary habits to avoid while taking Vanadom?

Official regulatory documents restrict the use of alcohol during treatment with Vanadom because of the risk of increased sedative effects. The medication itself can generally be administered with or without food.

Q: Does Vanadom interact with common pain relievers like ibuprofen or acetaminophen?

The official drug interaction profile primarily highlights known issues with other Central Nervous System (CNS) depressants, such as opioids and benzodiazepines. The single-ingredient label does not explicitly list non-opioid pain relievers like ibuprofen or acetaminophen as a major interaction.

Q: What happens in general if someone stops taking Vanadom suddenly?

The regulatory label notes that when Vanadom has been taken for a prolonged period, abrupt cessation may be associated with the development of withdrawal symptoms. These situations typically require guidance and monitoring from a healthcare professional.

Q: What is the meaning of a 'contraindication' related to taking Vanadom?

In the context of medication, a contraindication refers to a specific circumstance or health condition where the medicine is restricted from use because it may cause harm to the patient. For Vanadom, this includes conditions like acute intermittent porphyria.

Q: Are headaches a frequent initial experience for people starting Vanadom?

Official regulatory information indicates that headache is listed as a common adverse reaction related to the Central Nervous System. This classification describes the frequency of the event reported across study participants.

Q: Can people with diagnosed heart conditions use Vanadom without additional warnings?

The official labeling lists cardiovascular effects, such as tachycardia (a fast heart rate) and postural hypotension (a drop in blood pressure upon standing), as potential adverse reactions. These potential effects are part of the overall safety profile.

Q: Does the time of day Vanadom is taken affect its overall performance?

The official dosing schedule is structured to maintain therapeutic effects consistently throughout a 24-hour period. This regimen involves taking the medication multiple times a day, including a dose at bedtime.

Q: What are the key themes or general findings from recent Vanadom research updates?

The available evidence summarized in the official documentation focuses on the drug's short-term efficacy in managing acute musculoskeletal pain. The research base is generally limited in terms of long-term and comparative study data.

Q: Does Vanadom have any documented warnings regarding stomach bleeding or digestive upset?

The single-ingredient regulatory labeling lists general gastrointestinal effects, such as nausea and vomiting, as potential adverse reactions. It does not list specific warnings for stomach bleeding.

Q: Are there any specific warning signs that indicate a side effect may be serious and require medical attention?

Yes, the patient information included with the drug provides warnings to seek emergency medical help for signs of a severe allergic reaction. It also notes that serious effects such as seizures should be reported to a healthcare professional.

Q: Can people with specific allergies still use Vanadom?

Official documents state that the medication is restricted from use if there is a known hypersensitivity to Carisoprodol or its metabolite, Meprobamate. This is the main allergy-related restriction described in the prescribing information.

How should Vanadom be stored and disposed of?

How to Store and Dispose of Vanadom (Carisoprodol Tablets)

Vanadom must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medication requires protection from freezing, excessive heat, moisture, and direct light, and should be kept in a closed container in a dry place.

Child-Safety Storage

As a controlled substance, the tablets must be stored in a safe place and kept strictly out of the reach of children and pets to prevent accidental ingestion, which may lead to harm or death.

Disposal Requirements

Unused or expired Vanadom should be disposed of immediately using a local medication take-back program. If no program is available, the tablets must be mixed with an undesirable substance (such as cat litter or dirt) in a sealed bag before being placed in the household trash, as specified by regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vanadom found in:

A-Z Index: